Discovery of potential FGFR3 inhibitors via QSAR, pharmacophore modeling, virtual screening and molecular docking studies against bladder cancer

Abstract

Background Fibroblast growth factor receptor 3 is known as a favorable aim in vast range of cancers, particularly in bladder cancer treatment. Pharmacophore and QSAR modeling approaches are broadly utilized for developing novel compounds for the determination of inhibitory activity versus the biological target. In this study, these methods employed to identify FGFR3 potential inhibitors. Methods To find the potential compounds for bladder cancer targeting, ZINC and NCI databases were screened. Pharmacophore and QSAR modeling of FGFR3 inhibitors were utilized for dataset screening. Then, with regard to several factors such as Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) properties and Lipinski’s Rule of Five, the recognized compounds were filtered. In further step, utilizing the flexible docking technique, the obtained compounds interactions with FGFR3 were analyzed. Results The best five compounds, namely ZINC09045651, ZINC08433190, ZINC00702764, ZINC00710252 and ZINC00668789 were selected for Molecular Dynamics (MD) studies. Off-targeting of screened compounds was also investigated through CDD search and molecular docking. MD outcomes confirmed docking investigations and revealed that five selected compounds could make steady interactions with the FGFR3 and might have effective inhibitory potencies on FGFR3. Conclusion These compounds can be considered as candidates for bladder cancer therapy with improved therapeutic properties and less adverse effects.

Computer-Aided Drug Design in Anticancer Drugs

“…The selected compounds show promising interactions with FGFR3 and may have effective inhibitory properties. These compounds could be candidates for bladder cancer therapy with improved therapeutic properties and fewer adverse effects (Ganji et al, 2023). Someone discusses the use of pharmacophore modeling to identify potential inhibitors for the human cytochrome P450 17 enzyme, which is involved in producing androgens and is a target for prostate cancer therapy.…”